Gnrh analogues for treatment of urinary incontinence

Abstract

The use of at least one GnRH analogue for the preparation of a medicament for the prevention and/or treatment of side effects of ovarectomy or symptoms associated with reproductive senescence in female mammals, in particular urinary incontinence, hot flushes, and skin/hair changes are disclosed.

1 .- 20 . (canceled) 
   
   
       21 . A method for the treatment of urinary incontinence in a female mammal in need of such treatment comprising administering at least one GnRH analogue to said female mammal in an urinary incontinence in female mammals treating effective amount. 
   
   
       22 . A method of  claim 21 , wherein the GnRH analogue is at least one GnRH agonist or a GnRH antagonist. 
   
   
       23 . A method according to  claim 22  wherein said GnRH agonist results in a temporary overproduction of gonadotropins leading to a downregulation of follicle stimulating hormone (FSH) and/or luteinizing hormone (LH). 
   
   
       24 . A method according to  claim 22 , wherein said GnRH antagonist suppresses the activity of GnRH by binding GnRH receptors on target cells and thereby blocks its biological activity or decreases production/release of endogenous GnRH. 
   
   
       25 . The method of  claim 24 , wherein said GnRH antagonist is an antibody. 
   
   
       26 . The method of  claim 24 , wherein said GnRH antagonist is an antisense gene construct. 
   
   
       27 . A method according to  claim 21  or  22 , wherein a further active substance is administered to said individual, and wherein said substance is selected from the group consisting of an estrogenic agent, a partial estrogenic agent, a progestational agent and mixtures thereof. 
   
   
       28 . A method according to  claim 27 , wherein said estrogenic agent is estradiol valerate, a conjugated equine estrogen, 17β-estradiol, estrone or estriol; the partial estrogenic agent is raloxifene, centchroman, toremifen or tamoxifen; and the progestational agent is progesterone, hydroxygesterone, medroxyprogesterone, norethisterone, levonogestrel, norgestrel, gestodene or drospirenone. 
   
   
       29 . A method according to  claim 21  or  22 , wherein a further active substance is administered to said individual, and wherein said active substance is alpha-adrenergic agonist, beta adrenergic receptor blocking agent, cholinergic receptor blocking compound, cholinergic receptor stimulating drug, smooth muscle relaxant, nitric oxide synthase substrate, a nitric oxide donor, or a mixture thereof. 
   
   
       30 . A method according to  claim 21 , wherein at least said GnRH analogue is administered in a slow release formulation. 
   
   
       31 . A method according to  claim 21 , wherein said treatment consists essentially of administering at least one said GnRH analogue. 
   
   
       32 . A method according to  claim 22 , wherein at least said GnRH agonist or antagonist is administered in a slow release formulation. 
   
   
       33 . A method according to  claim 22 , wherein said treatment consists essentially of administering at least one GnRH agonist or antagonist. 
   
   
       34 . A method according to  claim 21  or  22 , wherein said female mammal is a human female pre-or postmenopausal, or a female dog. 
   
   
       35 . A method according to  claim 21 , wherein said at least one GnRH analogue is administered as part of a formulation for subcutaneous administration. 
   
   
       36 . A method according to  claim 21 , wherein said at least one GnRH analogue is administered as part of a formulation for parenteral, oral or rectal administration. 
   
   
       37 . A method according to  claim 21 , wherein said at least one GnRH analogue is administered as part of a formulation for intranasal, transdermal or intravaginal administration. 
   
   
       38 . A method according to  claim 22 , wherein said at least one GnRH agonist or antagonist is administered as part of a formulation for subcutaneous administration. 
   
   
       39 . A method according to  claim 22 , wherein said at least one GnRH agonist or antagonist is administered as part of a formulation for parenteral, oral or rectal administration. 
   
   
       40 . A method according to  claim 22 , wherein said at least one GnRH agonist or antagonist is administered as part of a formulation for intranasal, transdermal or intravaginal administration.